In addition to clinical status and imaging findings that reveal adverse cardiac remodeling and altered cardiac systolic and diastolic functions, circulating biomarkers—particularly N-terminal natriuretic peptide type B (NT-proBNP)—seem to be reliable tools for risk stratification, diagnosis and treatment of HF [6]. The gene discussed is NPPB; the disease is hydrops fetalis.